Shots:
- Horizon to acquire Viela Bio for $53/ share, representing an equity value of $3.05B with a 53% premium over a closing price to Viela’s on Jan 29, 2020. Additionally, AstraZeneca to divest its 26.7% ownership in Viela Bio in an exchange of ~$760 – $780M
- The transaction expected to close in Q1’21. The acquisition will bolster Horizon’s pipeline and expand its portfolio of rare diseases with the addition of Uplizna, VIB4920, VIB7734, VIB1116
- Previously, Horizon has submitted a prior approval supplement to the US FDA to support increased scale production of Tepezza for TED
Click here to read full press release/ article | Ref: Businesswire | Image: CFO
The post Horizon Therapeutics to Acquire Viela Bio for ~ $3.05B first appeared on PharmaShots.
